$75.5MSeries A, 9 July 2025
Funds clinical development of the lead FAP radioligand and pipeline expansion.
- Amount
- $75.5M
- Stage
- Series A
- Announced
- 9 July 2025
- Lead
- M Ventures
- Other investors
- Hadean Ventures, Sofinnova Partners, 4BIO Capital, Bioqube Ventures, Surveyor Capital, Arkin Bio Ventures
- Use of funds
- Funds clinical development of the lead FAP radioligand and pipeline expansion.
- Checked
- Announced by the company
- Sources
- Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy - PR Ne m-ventures.com
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy prnewswire.com